A Phase 4 interventional study of Aliskiren/Amlodipine and Amlodipine in Hypertension, sponsored by Novartis. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-30.
Sponsored by Novartis · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies testing aliskiren in Hypertension — none open to participants now, none under way, none of them phase 3. aliskiren · Hypertension.
Among the 89 studies testing aliskiren in Hypertension, this one is the 36th largest by enrollment, is one of 13 that started in 2009, is one of 34 in phase 4, and was the 54th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →None of the 89 studies testing aliskiren in Hypertension is open now. The open studies under Hypertension, anywhere →
aliskiren: first FDA approval 2007 (TEKTURNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 39 · Phase 4 34
First in 2001; this study’s year is marked. 13 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 443 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 253 across the 89 interventional studies. Of the 79 that completed or were terminated, 36 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
65 of 89 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
228 studies in Hypertension by Novartis: 5 open now, 6 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 228 studies in Hypertension by Novartis, this one is the 89th largest by enrollment of the 223 interventional ones that give a count, is one of 17 that started in 2009, is one of 67 in phase 4, and was the 161st registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 89 studies testing aliskiren in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 228 in Hypertension:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the BP-lowering efficacy of the combination of aliskiren and amlodipine, as initial therapy, compared to amlodipine monotherapy in African American patients with Stage II hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Evidence of a secondary form of hypertension, including but not limited to any of the following:
Other protocol defined inclusion/exclusion criteria applied
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
Drug: Aliskiren/Amlodipine
Amlodipine 5mg titrated to 10 mg
Drug: Amlodipine
Drug pages: AliskirenStudies of AliskirenAliskiren pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AmlodipineStudies of AmlodipineAmlodipine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
Amlodipine 5 mg titrated to 10mg
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
To compare the change from baseline in mean sitting systolic blood pressure (msSBP) after 8 weeks of treatment with a combination of aliskiren and amlodipine treatment regimen (150/5 mg, 300/10 mg) versus an amlodipine treatment regimen (5 mg, 10 mg) in African American patients with Stage 2 hypertension.
Time frame: Baseline, 8 weeks
Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)
To compare the change from baseline in mean sitting diastolic blood pressure (msDBP) after 8 weeks of treatment with a combination of aliskiren and amlodipine treatment regimen (150/5 mg, 300/10 mg) versus an amlodipine treatment regimen (5 mg, 10 mg).
Time frame: Baseline, 8 weeks
Percentage of Patients Achieving Blood Pressure (BP) Control (<140/90 mmHg)
Cumulative percentage of patients achieving BP control (\<140/90 mmHg)for both treatment arms was calculated. Cumulative refers to achieving blood pressure control before or at the corresponding visit. If achieving blood pressure control occurred more than once, only the first occurrence was counted.
Time frame: 8 weeks
Percentage of Responders (Patients With MSSBP < 140 mmHg or Decrease From Baseline of Greater Than or Equal to 20 mmHg)
Cumulative percentage of responders (Responders are defined as patients with MSSBP \<140 mmHg or a decrease from baseline ≥20 mmHg) during 8 weeks of treatment was calculated. Cumulative refers to achieving blood pressure control before or at the corresponding visit. If achieving blood pressure control occurred more than once, only the first occurrence was counted.
Time frame: 8 weeks
Change From Baseline in MSSBP at Week 1 and 4
Compare the change from baseline in MSSBP at week 1 and 4
Time frame: Baseline, 1 and 4 weeks
Percentage of Patients With Peripheral Edema by Visit
Cumulative percentage of patients with peripheral edema was calculated. 'Cumulative' refers to patients with peripheral edema before or at the corresponding visit. If peripheral edema occurred more than once, only the first occurrence was counted. Peripheral edema is the swelling of tissues due to the accumulation of fluids. Peripheral edema was assessed by investigators during physical examination.
Time frame: 8 weeks
| Milestone | Aliskiren/Amlodipine | Amlodipine |
|---|---|---|
| Started | 220 | 223 |
| Completed | 206 | 204 |
| Not completed | 14 | 19 |
| Withdrew: Adverse event | 9 | 3 |
| Withdrew: Unsatisfactory therapeutic effect | 0 | 2 |
| Withdrew: Subject withdrew consent | 4 | 5 |
| Withdrew: Lost to follow-up | 1 | 6 |
| Withdrew: Protocol deviation | 0 | 3 |
To compare the change from baseline in mean sitting systolic blood pressure (msSBP) after 8 weeks of treatment with a combination of aliskiren and amlodipine treatment regimen (150/5 mg, 300/10 mg) versus an amlodipine treatment regimen (5 mg, 10 mg) in African American patients with Stage 2 hypertension.
| mm Hg | Aliskiren/Amlodipine | Amlodipine |
|---|---|---|
| Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) | -33.1 ± 14.53 | -27.8 ± 13.45 |
To compare the change from baseline in mean sitting diastolic blood pressure (msDBP) after 8 weeks of treatment with a combination of aliskiren and amlodipine treatment regimen (150/5 mg, 300/10 mg) versus an amlodipine treatment regimen (5 mg, 10 mg).
| mm Hg | Aliskiren/Amlodipine | Amlodipine |
|---|---|---|
| Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) | -13.7 ± 9.60 | -10.4 ± 9.08 |
Cumulative percentage of patients achieving BP control (\<140/90 mmHg)for both treatment arms was calculated. Cumulative refers to achieving blood pressure control before or at the corresponding visit. If achieving blood pressure control occurred more than once, only the first occurrence was counted.
| Percentage of participants | Aliskiren/Amlodipine | Amlodipine |
|---|---|---|
| Percentage of Patients Achieving Blood Pressure (BP) Control (<140/90 mmHg) | 71.4 | 57.4 |
Cumulative percentage of responders (Responders are defined as patients with MSSBP \<140 mmHg or a decrease from baseline ≥20 mmHg) during 8 weeks of treatment was calculated. Cumulative refers to achieving blood pressure control before or at the corresponding visit. If achieving blood pressure control occurred more than once, only the first occurrence was counted.
| Percentage of participants | Aliskiren/Amlodipine | Amlodipine |
|---|---|---|
| Percentage of Responders (Patients With MSSBP < 140 mmHg or Decrease From Baseline of Greater Than or Equal to 20 mmHg) | 92.3 | 86.5 |
Compare the change from baseline in MSSBP at week 1 and 4
| mm Hg | Aliskiren/Amlodipine | Amlodipine |
|---|---|---|
| Baseline to Week 1 | -20.5 ± 12.53 | -18.2 ± 13.01 |
| baseline to Week 4 | -30.9 ± 13.30 | -27.3 ± 13.58 |
Cumulative percentage of patients with peripheral edema was calculated. 'Cumulative' refers to patients with peripheral edema before or at the corresponding visit. If peripheral edema occurred more than once, only the first occurrence was counted. Peripheral edema is the swelling of tissues due to the accumulation of fluids. Peripheral edema was assessed by investigators during physical examination.
| Percentage of participants | Aliskiren/Amlodipine | Amlodipine |
|---|---|---|
| Week 1 | 1.4 | 1.3 |
| Week 4 | 4.1 | 5.8 |
| Week 8 | 6.8 | 8.5 |
Collected over 8 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aliskiren/Amlodipine | — | 1/220 (0.5%) | 25/220 (11.4%) |
| Amlodipine | — | 1/223 (0.4%) | 31/223 (13.9%) |
| Event | Aliskiren/Amlodipine | Amlodipine |
|---|---|---|
| Angina unstableCardiac disorders | 1/220 | 0/223 |
| PneumoniaInfections and infestations | 0/220 | 1/223 |
| Back painMusculoskeletal and connective tissue disorders | 0/220 | 1/223 |
| Event | Aliskiren/Amlodipine | Amlodipine |
|---|---|---|
| Oedema peripheralGeneral disorders | 17/220 | 20/223 |
| HeadacheNervous system disorders | 8/220 | 12/223 |
| Age Continuous(years) | Aliskiren/Amlodipine | Amlodipine | Total |
|---|---|---|---|
| Mean | 53.2 ± 9.33 | 52.4 ± 10.57 | 52.8 ± 9.97 |
| Age, Customized(participants) | Aliskiren/Amlodipine | Amlodipine | Total |
|---|---|---|---|
| <55 years | 123 | 127 | 250 |
| ≥55 years | 97 | 96 | 193 |
| Sex: Female, Male(Participants) | Aliskiren/Amlodipine | Amlodipine | Total |
|---|---|---|---|
| Female | 123 | 115 | 238 |
| Male | 97 | 108 | 205 |
The record gives a start of Feb 2009, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aliskiren · Amlodipine